Investigation of Prolactin Receptor Activation and Blockade Using Time-Resolved Fluorescence Resonance Energy Transfer

The prolactin receptor (PRLR) is emerging as a therapeutic target in oncology. Knowledge-based drug design led to the development of a pure PRLR antagonist (Del1-9-G129R-hPRL) that was recently shown to prevent PRL-induced mouse prostate tumorogenesis. In humans, the first gain-of-function mutation...

Descripción completa

Detalles Bibliográficos
Autores principales: Tallet, Estelle, Fernandez, Isabelle, Zhang, Chi, Salsac, Marion, Gregor, Nathalie, Ayoub, Mohammed Akli, Pin, Jean Philippe, Trinquet, Eric, Goffin, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Research Foundation 2011
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3355858/
https://www.ncbi.nlm.nih.gov/pubmed/22649370
http://dx.doi.org/10.3389/fendo.2011.00029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3355858/
https://www.ncbi.nlm.nih.gov/pubmed/22649370
http://dx.doi.org/10.3389/fendo.2011.00029

Ejemplares similares